Associated Papers
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndrome.
Montellier E et al.
Ebiomedicine, 2026
41370968 (PubMed )
Supplement: mmc2.xlsx › Table_S1
A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome.
Fortuno C et al.
Genome Medicine, 2025
41126324 (PubMed )
Supplement: 13073_2025_1536_MOESM2_ESM.xlsx › Table_S2
USP8, USP48, BRAF and TP53 mutations in crooke cell adenoma.
Kober P et al.
Pituitary, 2025
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome.
Montellier E et al.
Iscience, 2024
39634561 (PubMed )
Supplement: mmc2.xlsx › TableS1
Mutations in the TP53, VEGFA, and CTH Genes as Key Molecular Markers for the Diagnosis of Glioblastoma.
Khalil SS et al.
Cureus, 2024
Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types.
Sasaki K et al.
Scientific Reports, 2023
36964217 (PubMed )
Supplement: 41598_2023_32092_MOESM1_ESM.xlsx › Suppl._table_S1
Molecular and clinicopathological analysis revealed an immuno-checkpoint inhibitor as a potential therapeutic target in a subset of high-grade myxofibrosarcoma.
Yamashita A et al.
Virchows Archiv : an International Journal of Pathology, 2022
Design and MinION testing of a nanopore targeted gene sequencing panel for chronic lymphocytic leukemia.
Orsini P et al.
Scientific Reports, 2018
30087429 (PubMed )
Supplement: 41598_2018_30330_MOESM3_ESM.xlsx › recurrent_mutations
Mutation allele frequency threshold does not affect prognostic analysis using next-generation sequencing in oral squamous cell carcinoma.
Ma J et al.
Bmc Cancer, 2018
Germ-line and somatic EPHA2 coding variants in lens aging and cataract.
Bennett TM et al.
Plos One, 2017
29267365 (PubMed )
Supplement: pone.0189881.s007.xlsx › S7a._Clear__1__all
Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?
Costa DC et al.
Cold Spring Harbor Perspectives in Biology, 2016
Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.
de Oliveira GA et al.
Frontiers in Oncology, 2015
High frequency of complex TP53 mutations in CNS metastases from breast cancer.
Lo Nigro C et al.
British Journal of Cancer, 2012
Structural basis for gene activation by p53 family members.
Scoumanne A et al.
Cancer Biology & Therapy, 2005
Select a paper to view details